The global Minimally Invasive Glaucoma Surgery (MIGS) devices market generated $298.75 million in 2020 and is projected to reach $5,099.38 million by 2030, registering an extraordinary CAGR of 35.0% from 2021 to 2030. This tremendous growth is fueled by a rising preference for MIGS over traditional glaucoma surgeries due to their safety profile, effectiveness, and ability to significantly lower intraocular pressure (IOP) with fewer complications.
Understanding MIGS Devices
MIGS represents a transformative approach to glaucoma treatment. These devices—such as stents, shunts, and micro-implants—are designed to minimally disrupt ocular tissues while effectively improving aqueous humor outflow, thereby reducing IOP. Unlike conventional glaucoma surgeries, which often involve extensive tissue dissection, MIGS procedures are less invasive, require shorter recovery times, and pose lower risks, making them particularly suitable for patients with mild to moderate glaucoma.
Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/4547
Key Market Drivers
1. Surge in Glaucoma Cases
The increasing global prevalence of glaucoma, particularly in the elderly population, is one of the most significant drivers. Glaucoma is a leading cause of irreversible blindness, and its progression can be slowed with early detection and effective IOP management. The World Health Organization estimates that over 76 million people worldwide are living with glaucoma—a number that continues to rise with aging demographics.
2. Shift Toward Combined Procedures
There is a growing demand for combined cataract and glaucoma surgeries, where MIGS devices are frequently used in conjunction with cataract procedures. These dual interventions are both cost-effective and clinically efficient, reducing the number of surgeries and improving patient compliance.
3. Innovation and Product Development
Major players are focusing on the development of advanced MIGS stents and implants. Companies such as AbbVie, following its acquisition of Allergan, have expanded their portfolio with innovative products like XEN Gel Stent, Durysta, and Ozurdex, reinforcing their presence in the eye care domain.
Market Challenges
While the market outlook is overwhelmingly positive, several challenges persist:
Reimbursement issues in several countries hinder market access and adoption.
A limited pool of trained ophthalmic surgeons skilled in MIGS procedures.
Initial high costs of devices may deter smaller clinics from adoption.
Despite these hurdles, ongoing training programs, regulatory support, and improved reimbursement policies in developed markets are expected to address these barriers over time.
Impact of COVID-19
The COVID-19 pandemic temporarily slowed the momentum of the MIGS devices market. As ophthalmic surgeries were postponed and hospitals prioritized emergency care, elective procedures like MIGS saw a decline. However, as elective surgeries resumed, the market began recovering quickly, especially with a renewed focus on minimally invasive procedures that require shorter hospital stays and lower complication risks—ideal during post-pandemic recovery.
Market Segmentation Insights
By Surgery Type
Standalone Glaucoma Surgery dominated the market in 2020 due to the growing patient base of primary open-angle glaucoma and other chronic forms.
However, glaucoma combined with cataract surgery is gaining popularity as a bundled approach to treat age-related ocular conditions simultaneously.
By Target Area
Trabecular Meshwork Segment is projected to grow significantly, as most MIGS procedures target this region to enhance aqueous outflow. The ineffectiveness of traditional medications in many patients is prompting a shift toward surgical options.
By Product Type
MIGS Stents held the largest share in 2020, and this trend is expected to continue. Their low complication rate, ease of insertion, and proven efficacy make them a go-to solution for ophthalmologists.
MIGS Shunts and other devices are also gaining momentum, particularly with newer generations of devices that provide durable IOP control with minimal trauma.
By End User
Eye Hospitals accounted for the highest market share in 2020. Their access to advanced infrastructure and skilled ophthalmologists positions them as key adopters of MIGS technologies.
Ophthalmology Clinics and Ambulatory Surgical Centers (ASCs) are expected to grow steadily, driven by rising awareness and investments in outpatient care settings.
Regional Overview
North America
Dominated the global MIGS devices market in 2020.
The region’s growth is propelled by:
High glaucoma prevalence
Favorable regulatory environment
Presence of leading market players such as Glaukos and AbbVie
Strong reimbursement structures
Asia-Pacific
Expected to exhibit the fastest growth during the forecast period.
Drivers include:
A rapidly aging population
Increased awareness about eye health
Rising demand for affordable glaucoma treatment
Expansion of ophthalmology services in countries like India, China, and Japan
Europe and LAMEA
Europe remains a robust market due to its universal healthcare systems and early adoption of advanced medical technologies.
The LAMEA region shows emerging potential, with increasing healthcare investments and improving diagnostic capabilities.
Key Market Players
Leading players shaping the global MIGS devices market include:
AbbVie Inc.
Glaukos Corporation
iSTAR Medical SA
Ivantis Inc.
Lumenis Ltd.
Asico LLC
Ziemer Ophthalmic Systems AG
Novartis International AG
Santen Pharmaceutical Co., Ltd.
Carl Zeiss Meditec AG
These companies are focusing on product innovation, strategic acquisitions, and geographic expansion to gain a competitive edge. Mergers like AbbVie’s acquisition of Allergan have consolidated eye care offerings under large pharmaceutical umbrellas, increasing their global reach.
Future Outlook
The future of the MIGS devices market lies in:
Integration with digital diagnostics for better surgical planning.
Customized MIGS implants tailored to individual ocular anatomy.
Robotic-assisted surgeries to improve precision and minimize human error.
Expansion into emerging markets, where demand is high and competition is relatively low.
Conclusion
The Minimally Invasive Glaucoma Surgery (MIGS) devices market is on a powerful upward trajectory, driven by an aging population, rising glaucoma incidence, and growing demand for less invasive surgical alternatives. As technology continues to advance and awareness spreads globally, MIGS devices are well-positioned to become the standard of care in glaucoma treatment, replacing traditional surgeries in many clinical settings.
